Dimerix Limited (DXB.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.205 (+2.50%) as of
Key statistics
- Market cap
- 123.08M
- Forward P/E
- -10.25
- EPS (TTM)
- -0.0500
- Dividend yield
- 0.00%
- 52-week range
- 0.1575 – 0.6650
- Beta
- 0.35
- Revenue (TTM)
- 6.35M
- Profit margin
- 0.00%
- Analyst target
- A$1.90
- Volume
- 58.94k
About Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Fitzroy, VIC, Australia
- Employees
- 15
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.